Fungicidal activity and morphological alterations of Candida albicans induced by echinocandins: Study of strains with reduced caspofungin susceptibility

Mycoses

Volumn 54, Issue 4, 2011, Pages

  Dunyach, Catherine ^a   Drakulovski, Pascal ^a   Bertout, Sébastien ^a   Jouvert, Sylvie ^a   Reynes, Jacques ^b   Mallié, Michèle ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Candida albicans; Caspofungin; Fungicidal activity; Non susceptible strain

Indexed keywords

CASPOFUNGIN;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; FUNGAL CELL; FUNGAL MORPHOLOGY; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CELL WALL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION;

CANDIDA ALBICANS;

EID: 79959231132     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01834.x     Document Type: Article

References (23)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
2. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-10.
3. Ascioglu S, Rex JH, Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
4. Ruiz-Herrera J, Elorza MV, Valentin E, Sentandreu R. Molecular organization of the cell wall of Candida albicans and its relation to pathogenicity. FEMS Yeast Res 2006; 6: 14-29.
5. Bishop CT, Blank F, Gardner PE. The cell wall polysaccharides of Candida albicans: glucan, mannan, and chitin. Can J Chem 1960; 38: 869-81.
6. Masuoka J. Surface glycans of Candida albicans and other pathogenic fungi: Physiological roles, clinical uses, and experimental challenges. Clin Microbiol Rev 2004; 17: 281-310.
7. Letsher-Bru V, Herbrecht R. Caspofungin: the first representative of a new class. J Antimicrob Chemother 2003; 51: 513-21.
8. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-57.
9. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-30.
10. Mora-Duarte J, Betts R, Rotstein C et al. Comparaison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
11. Pfaller MA, Messer SA, Mills K, Bolmstrom A, Jones RN. Evaluation of E-test method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J Clin Microbiol 2001; 39: 4387-9.
12. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretative MIC breakpoints. J Clin Microbiol 2008; 46: 2620-929.
13. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 3rd edn. Approved standard M27-A3. Wayne, PA: CLSI; 2008.
14. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high concentrations. Antimicrob Agents Chemother 2004; 48: 3407-11.
15. Miègeville M, Morin O. New scanning electron microscopy contribution to the study of yeast protoplast. C R Acad Sci (Paris) 1977; 284: 1935-8.
16. Bastide M, Jouvert S, Bastide JM. Cytolgical study of the action of imidazoles on Candida albicans. Pathol Biol 1982; 30: 458-62.
17. Mallié M, Jouvert S, Montès B, Lebecq JC, Bastide JM. Comparative action of 8 azole derivatives against Candida albicans: fungistatic action and cytologic study by scanning electron microscopy. Pathol Biol 1988; 36: 575-80.
18. Jayatilake JAMS, Samaranayake YH, Samaranayake LP. An ultrastructural and a cytochemical study of candidal invasion of reconstituted human oral epithelium. J Oral Pathol Med 2005; 34: 240-6.
19. Pfaller MA, Boyken L, Hollis RJ et al. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol 2006; 44: 3533-8.
20. Kartsonis N, Killar J, Mixson L et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005; 49: 3616-23.
21. Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc 2002; 51: 247-55.
22. Odds FC. Activity of cilofungin (LY121019) against Candida species in vitro. J Antimicrob Chemother 1988; 22: 891.
23. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1, 6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006; 50: 3160-1.